EMA Starts Rolling Review Of CureVac’s COVID-19 Vaccine
CureVac has submitted the pre-clinical data package for its COVID-19 vaccine to the European Medicines Agency, which will be reviewing the data on a rolling basis.
You may also be interested in...
The Swiss major, which is already signed up to help produce Pfizer and BioNTech's COVID-19 vaccine, is offering its services to CureVac to produce its mRNA vaccine.
The agreement focuses on respiratory viruses, especially influenza, and includes a $225m upfront payment plus an increase in GSK’s equity investment in Vir.
There is some good news from UK and EU vaccine safety reviews, the WHO reports on COVAX vaccine distribution to less well off countries, and the European Commission and Pfizer agree on the supply of 300 million more vaccine doses.